Insys Therapeutics Company Profile (NASDAQ:INSY)

About Insys Therapeutics

Insys Therapeutics logoInsys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: INSY
  • CUSIP:
Key Metrics:
  • Previous Close: $12.72
  • 50 Day Moving Average: $15.19
  • 200 Day Moving Average: $15.19
  • 52-Week Range: $11.45 - $33.88
  • Trailing P/E Ratio: 19.16
  • Foreward P/E Ratio: 21.20
  • P/E Growth: 1.31
  • Market Cap: $910.69M
  • Outstanding Shares: 71,595,000
  • Beta: 1.93
Profitability:
  • Net Margins: 16.03%
  • Return on Equity: 20.08%
  • Return on Assets: 15.11%
Debt:
  • Current Ratio: 3.28%
  • Quick Ratio: 2.87%
Additional Links:
Companies Related to Insys Therapeutics:

Analyst Ratings

Consensus Ratings for Insys Therapeutics (NASDAQ:INSY) (?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $25.67 (101.78% upside)

Analysts' Ratings History for Insys Therapeutics (NASDAQ:INSY)
Show:
DateFirmActionRatingPrice TargetDetails
9/23/2016RBC Capital MarketsReiterated RatingOutperform$32.00 -> $26.00View Rating Details
9/22/2016Royal Bank Of CanadaLower Price TargetOutperform$32.00 -> $26.00View Rating Details
8/25/2016Piper Jaffray Cos.Reiterated RatingOverweight$28.00View Rating Details
8/4/2016Jefferies GroupReiterated RatingBuy$17.00 -> $22.00View Rating Details
4/30/2016Oppenheimer Holdings Inc.Reiterated RatingHoldView Rating Details
4/14/2016Janney Montgomery ScottInitiated CoverageBuy$22.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$38.00 -> $30.00View Rating Details
(Data available from 9/29/2014 forward)

Earnings

Earnings History for Insys Therapeutics (NASDAQ:INSY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/3/2016Q216$0.07$0.06$66.90 million$67.10 millionViewListenView Earnings Details
4/28/2016Q116$0.07$0.11$61.31 million$62.00 millionViewListenView Earnings Details
2/23/2016Q415$0.29$0.36$91.04 million$91.10 millionViewListenView Earnings Details
11/5/2015Q315$0.23$0.50$82.98 million$91.30 millionViewN/AView Earnings Details
8/6/2015Q215$0.21$0.21$74.06 million$77.60 millionViewN/AView Earnings Details
5/7/2015Q115$0.35$0.63$70.90 million$70.80 millionViewN/AView Earnings Details
3/3/2015Q414$0.44$0.53$63.50 million$66.50 millionViewN/AView Earnings Details
11/11/2014Q314$0.29$0.63$57.10 million$58.30 millionViewN/AView Earnings Details
8/12/2014Q214$0.30$0.58$52.77 million$55.70 millionViewN/AView Earnings Details
5/13/2014Q114$0.28$0.23$45.63 million$41.60 millionViewN/AView Earnings Details
3/4/2014Q413$0.55$0.71$34.73 million$40.20 millionViewN/AView Earnings Details
11/12/2013Q3$0.33$0.58$27.00 million$29.20 millionViewListenView Earnings Details
8/13/2013Q213$0.12$0.35$15.07 million$18.80 millionViewN/AView Earnings Details
6/3/2013Q113$0.01$2.00 million$11.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Insys Therapeutics (NASDAQ:INSY)
Current Year EPS Consensus Estimate: $0.19 EPS
Next Year EPS Consensus Estimate: $0.6 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.05$0.05$0.05
Q2 20161$0.04$0.04$0.04
Q3 20161$0.10$0.10$0.10
Q4 20161$0.13$0.13$0.13
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Insys Therapeutics (NASDAQ:INSY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Insys Therapeutics (NASDAQ:INSY)
Insider Ownership Percentage: 69.20%
Institutional Ownership Percentage: 47.37%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/16/2016Theodore H StanleyDirectorSell15,000$18.02$270,300.00View SEC Filing  
8/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy5,700$18.57$105,849.00View SEC Filing  
8/11/2016Patrick FourteauDirectorSell15,000$18.46$276,900.00View SEC Filing  
8/9/2016Daniel BrennanVPSell5,781$19.16$110,763.96View SEC Filing  
6/6/2016Theodore H StanleyDirectorSell16,000$16.27$260,320.00View SEC Filing  
5/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy50,000$12.84$642,000.00View SEC Filing  
3/4/2016Patrick FourteauDirectorSell15,000$18.22$273,300.00View SEC Filing  
11/17/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy5,000$29.50$147,500.00View SEC Filing  
11/12/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy10,000$26.58$265,800.00View SEC Filing  
11/12/2015Patrick FourteauDirectorSell30,000$26.48$794,400.00View SEC Filing  
9/14/2015Theodore H. StanleyDirectorSell4,000$37.04$148,160.00View SEC Filing  
6/10/2015Fosse Franc DelGeneral CounselSell10,000$34.48$344,800.00View SEC Filing  
6/5/2015Steven J MeyerDirectorSell5,000$63.00$315,000.00View SEC Filing  
5/27/2015Brian TambiDirectorSell3,100$60.09$186,279.00View SEC Filing  
5/26/2015Brian TambiDirectorSell1,800$60.00$108,000.00View SEC Filing  
5/20/2015Patrick FourteauDirectorSell9,064$60.00$543,840.00View SEC Filing  
5/18/2015Darryl S BakerCFOSell10,000$59.17$591,700.00View SEC Filing  
5/11/2015Steven J MeyerDirectorSell18,000$57.06$1,027,080.00View SEC Filing  
3/17/2015Michael L BabichCEOSell75,000$58.63$4,397,250.00View SEC Filing  
3/11/2015Patrick FourteauDirectorSell10,000$59.94$599,400.00View SEC Filing  
3/10/2015Theodore H StanleyDirectorSell3,300$60.03$198,099.00View SEC Filing  
2/9/2015Darryl S BakerCFOSell30,000$52.23$1,566,900.00View SEC Filing  
11/19/2014Patrick FourteauDirectorSell25,000$39.11$977,750.00View SEC Filing  
11/4/2014Michael L BabichCEOSell80,000$38.66$3,092,800.00View SEC Filing  
8/13/2014Theodore H StanleyDirectorBuy3,000$33.93$101,790.00View SEC Filing  
6/16/2014John N KapoorDirectorBuy5,000$26.13$130,650.00View SEC Filing  
6/13/2014John N KapoorDirectorBuy5,000$25.44$127,200.00View SEC Filing  
6/12/2014John N KapoorDirectorBuy20,000$24.84$496,800.00View SEC Filing  
6/11/2014John N KapoorDirectorBuy20,000$24.54$490,800.00View SEC Filing  
5/19/2014Theodore StanleyDirectorBuy4,000$21.94$87,760.00View SEC Filing  
5/15/2014Patrick FourteauDirectorBuy7,500$22.77$170,775.00View SEC Filing  
3/5/2014Larry DillahaInsiderSell149,932$74.57$11,180,429.24View SEC Filing  
3/5/2014Michael BabichCEOSell288,432$74.58$21,511,258.56View SEC Filing  
1/16/2014Darryl BakerCFOSell10,000$49.61$496,100.00View SEC Filing  
1/15/2014Darryl BakerCFOSell10,000$47.54$475,400.00View SEC Filing  
1/14/2014Darryl BakerCFOSell10,000$45.64$456,400.00View SEC Filing  
12/9/2013John KapoorDirectorSell27,428$47.25$1,295,973.00View SEC Filing  
8/16/2013Michael BabichCEOBuy1,000$24.90$24,900.00View SEC Filing  
8/14/2013Patrick FourteauDirectorBuy5,000$23.77$118,850.00View SEC Filing  
6/4/2013Michael L BabichCEOBuy1,250$10.93$13,662.50View SEC Filing  
5/24/2013Pierre LapalmeDirectorBuy3,000$10.39$31,170.00View SEC Filing  
5/14/2013Patrick FourteauDirectorBuy5,000$10.90$54,500.00View SEC Filing  
5/13/2013Patrick FourteauDirectorBuy4,800$10.90$52,320.00View SEC Filing  
5/7/2013Patrick FourteauDirectorBuy50,000$8.36$418,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Insys Therapeutics (NASDAQ:INSY)
DateHeadline
News IconTrading the Biotech News: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), INSYS Therapeutics, Inc. (NASDAQ:INSY) - The Voice Registrar (NASDAQ:INSY)
voiceregistrar.com - September 26 at 5:44 PM
News IconDrug companies fight medical marijuana (NASDAQ:INSY)
www.arktimes.com - September 25 at 5:02 PM
News IconBiotech Stocks Worth a Closer Look: Incyte Corporation (NASDAQ:INCY), INSYS Therapeutics, Inc. (NASDAQ:INSY) - The Voice Registrar (NASDAQ:INSY)
voiceregistrar.com - September 23 at 5:18 PM
News IconNews review of 2 biotech stocks: Amicus Therapeutics, Inc. (NASDAQ:FOLD), INSYS Therapeutics, Inc. (NASDAQ:INSY) - The Voice Registrar (NASDAQ:INSY)
voiceregistrar.com - September 22 at 3:41 PM
reuters.com logoBRIEF-Insys Therapeutics announces CEO succession plan | Reuters - Reuters (NASDAQ:INSY)
www.reuters.com - September 22 at 8:50 AM
finance.yahoo.com logoInsys Therapeutics Announces CEO Succession Plan - Yahoo Finance (NASDAQ:INSY)
finance.yahoo.com - September 22 at 8:50 AM
forbes.com logoCannabis Attracting Mainstream Research Analysts (NASDAQ:INSY)
www.forbes.com - September 22 at 8:50 AM
reuters.com logoBRIEF-Insys Therapeutics announces CEO succession plan (NASDAQ:INSY)
www.reuters.com - September 21 at 3:53 PM
4-traders.com logoINSYS THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) (NASDAQ:INSY)
www.4-traders.com - September 21 at 3:53 PM
streetinsider.com logoInsys Therapeutics (INSY) Initiates Search for New CEO (NASDAQ:INSY)
www.streetinsider.com - September 21 at 3:52 PM
finance.yahoo.com logoInsys Therapeutics Announces CEO Succession Plan (NASDAQ:INSY)
finance.yahoo.com - September 21 at 3:52 PM
biz.yahoo.com logoINSYS THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:INSY)
biz.yahoo.com - September 21 at 3:52 PM
reuters.com logoBRIEF-Insys Therapeutics announces CEO succession plan - Reuters (NASDAQ:INSY)
in.reuters.com - September 21 at 9:50 AM
News IconInsys Therapeutics Announces CEO Succession Plan - EconoTimes (NASDAQ:INSY)
www.econotimes.com - September 21 at 9:50 AM
News IconINSYS Therapeutics, Inc Pipeline Review, Industry Study, Research and Clinical trial 2016 - 2020 - Medgadget (blog) (NASDAQ:INSY)
www.medgadget.com - September 19 at 5:41 PM
News IconBig Pharma Fights Marijuana Legalization to Save Its Own Profits (NASDAQ:INSY)
newsununity.com - September 19 at 10:11 AM
News IconMaker Of Opiate Painkiller Stronger Than Heroin Is Working To Defeat Marijuana Legalization (NASDAQ:INSY)
www.deprogramyourself.org - September 19 at 10:11 AM
News IconINSYS Therapeutics, Inc Pipeline Review, Industry Study, Research and Clinical trial 2016 – 2020 (NASDAQ:INSY)
www.medgadget.com - September 18 at 10:04 AM
News IconDr. Titus Insights: Biotechs and Cannabis (NASDAQ:INSY)
www.medicalmarijuanainc.com - September 16 at 5:30 PM
News IconFentanyl Company is Fighting Legalization so They Can Release Synthetic THC Spray (NASDAQ:INSY)
www.marijuanatimes.org - September 16 at 5:30 PM
News IconBig Pharma company fights marijuana legalization to save its own profits (NASDAQ:INSY)
newstarget.com - September 16 at 5:30 PM
News IconFentanyl Company is Fighting Legalization so They Can Release Synthetic THC Spray - The Marijuana Times (NASDAQ:INSY)
www.marijuanatimes.org - September 16 at 9:33 AM
News IconInsys Therapeutics Inc against weed legalization - Business Insider - Business Insider (NASDAQ:INSY)
uk.businessinsider.com - September 15 at 8:49 AM
News IconSteering Attention Towards Earnings; Analysts Weigh in on Insys Therapeutics, Inc. (NASDAQ:INSY) Stock - Frisco Fastball (NASDAQ:INSY)
friscofastball.com - September 14 at 5:45 PM
News IconPharma Company Funding Anti-Pot Fight Worried About Losing ... - The Intercept (NASDAQ:INSY)
theintercept.com - September 14 at 5:45 PM
News IconOpioid Company Contributes $500k to Anti-Cannabis Group (NASDAQ:INSY)
thechillbud.com - September 13 at 10:27 AM
News IconPharma Company Funding Anti-Pot Fight Worried About Losing Business, Filings Show (NASDAQ:INSY)
theintercept.com - September 13 at 10:27 AM
News IconBig Pharma Donates $500,000 To Try To Keep Weed Illegal (NASDAQ:INSY)
www.weedweekly.com - September 13 at 10:27 AM
News IconTrading the Biotech News: INSYS Therapeutics, Inc. (NASDAQ:INSY), Sangamo Biosciences Inc. (NASDAQ:SGMO) - The Voice Registrar (NASDAQ:INSY)
voiceregistrar.com - September 12 at 5:30 PM
News IconMaker Of Drug Fueling Heroin Overdose Epidemic Is Lobbying To Keep Weed Illegal (NASDAQ:INSY)
www.zerohedge.com - September 12 at 10:22 AM
News IconFentanyl Maker Donates Big to Campaign Opposing Pot Legalization - U.S. News & World Report (NASDAQ:INSY)
www.usnews.com - September 10 at 10:03 AM
News IconProp. 205 Camp Slams Opposition Group for Taking Huge Big Pharma Donation (NASDAQ:INSY)
www.thedailychronic.net - September 9 at 5:27 PM
News IconPainkiller Company Makes Huge Donation Against Marijuana Legalization (NASDAQ:INSY)
www.americanow.com - September 9 at 5:27 PM
News IconArizona Drug Firm Insys Makes Synthetic Pot Compound, Spends Big to Defeat Legal Pot (NASDAQ:INSY)
www.phoenixnewtimes.com - September 9 at 5:27 PM
capitalcube.com logoINSYS Therapeutics, Inc. – Value Analysis (NASDAQ:INSY) : September 9, 2016 (NASDAQ:INSY)
www.capitalcube.com - September 9 at 5:27 PM
News IconPlacing Insys Therapeutics, Inc. (NASDAQ:INSY) Shares Under the Microscope - Post News (NASDAQ:INSY)
www.kentuckypostnews.com - September 9 at 10:21 AM
capitalcube.com logoINSYS Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : INSY-US : September 8, 2016 (NASDAQ:INSY)
www.capitalcube.com - September 8 at 9:35 AM
investors.com logoGW Pharmaceuticals Stock Pops On Report Of Buyout Interest (NASDAQ:INSY)
www.investors.com - September 7 at 5:50 PM
News IconSeizures Therapeutics Drugs and Companies Pipeline Review, H2 2016 (NASDAQ:INSY)
www.medgadget.com - September 6 at 10:26 AM
finance.yahoo.com logoWhat Makes INSYS Therapeutics (INSY) a Strong Sell? (NASDAQ:INSY)
finance.yahoo.com - September 6 at 10:26 AM
globenewswire.com logoInsys Therapeutics, Inc. to Present at Morgan Stanley Global Healthcare Conference - GlobeNewswire (press release) (NASDAQ:INSY)
globenewswire.com - September 2 at 5:35 PM
News IconBiotech Stocks Worth a Closer Look: INSYS Therapeutics, Inc ... - The Voice Registrar (NASDAQ:INSY)
voiceregistrar.com - September 1 at 8:37 AM
finance.yahoo.com logoInsys Therapeutics, Inc. to Present at Morgan Stanley Global Healthcare Conference (NASDAQ:INSY)
finance.yahoo.com - September 1 at 8:37 AM
prnewswire.com logoPurcell Julie & Lefkowitz LLP Is Investigating Insys Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By ... - PR Newswire (press release) (NASDAQ:INSY)
www.prnewswire.com - August 31 at 10:27 AM
News Icon$INSY Is Being Investigated for Potential Breaches Of Fiduciary Duty (NASDAQ:INSY)
marijuanastocks.com - August 30 at 5:43 PM
News IconPharma company Insys marketed opioid drug at high-volume prescribers – lawsuit (NASDAQ:INSY)
www.rt.com - August 30 at 8:53 AM
finance.yahoo.com logoPurcell Julie & Lefkowitz LLP Is Investigating Insys Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors (NASDAQ:INSY)
finance.yahoo.com - August 30 at 8:53 AM
News IconNew Broker Ratings For Insys Therapeutics, Inc. (INSY) (NASDAQ:INSY)
magseriesusa.net - August 27 at 10:08 AM
reuters.com logoBRIEF-Insys Therapeutics says in study all treatments were generally well tolerated (NASDAQ:INSY)
www.reuters.com - August 26 at 5:31 PM
streetinsider.com logoInsys Therapeutics (INSY) Announces Buprenorphine Sublingual Spray Phase 3 Met Primary Endpoint - StreetInsider.com (NASDAQ:INSY)
www.streetinsider.com - August 26 at 8:39 AM

Social

Insys Therapeutics (NASDAQ:INSY) Chart for Thursday, September, 29, 2016


Last Updated on 9/29/2016 by MarketBeat.com Staff